Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
908 DevicesMASS +4.84%71 3-Year EBITDA Growth Rate is 16.40% as of Mar. 2026. GuruFocus rates MASS with a GF Score™ of 71/100 and a GF Value™ of $7.06 (Modestly Overvalued). The stock has 7 warning signs investors should review. Among 693 Medical Devices & Instruments companies, 908 Devices ranks better than 61.18% on this metric.
During the past 3 years, the average EBITDA Per Share Growth Rate was 16.40% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 15.90% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 8 years, the highest 3-Year average EBITDA Per Share Growth Rate of 908 Devices was 19.30% per year. The lowest was -36.90% per year. And the median was 0.00% per year.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
908 Devices 3-Year EBITDA Growth Rate Related Terms
MASS vs ELMD, SGHT, LAB: 3-Year EBITDA Growth Rate Comparison
For the Medical Devices subindustry, 908 Devices's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
908 Devices 3-Year EBITDA Growth Rate vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, 908 Devices's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where 908 Devices's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 16.40% mean?
908 Devices (MASS) has a 3-Year EBITDA Growth Rate of 16.40% as of Mar. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for 908 Devices and its competitors. According to the industry distribution chart, 908 Devices ranks #269 out of 693 companies in the Medical Devices & Instruments industry, placing it in the top 38.8%.
Is 908 Devices' 3-Year EBITDA Growth Rate too high?
908 Devices' current 3-Year EBITDA Growth Rate is 16.40%. The Medical Devices & Instruments industry median 3-Year EBITDA Growth Rate is 8.10. 908 Devices' value of 16.40% is 102.5% above this industry median. Based on the distribution chart, 908 Devices ranks #269 out of 693 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, 908 Devices has a GF Score™ of 71/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does 908 Devices' 3-Year EBITDA Growth Rate compare to ELMD and SGHT?
According to the Medical Devices & Instruments industry distribution chart, 908 Devices ranks #269 out of 693 companies for 3-Year EBITDA Growth Rate. This puts 908 Devices in the upper half of its industry. The industry median 3-Year EBITDA Growth Rate is 8.10. 908 Devices' value of 16.40% is 102.5% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Medical Devices & Instruments company?
The median 3-Year EBITDA Growth Rate among Medical Devices & Instruments companies is 8.10, based on 693 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. 908 Devices's current 3-Year EBITDA Growth Rate of 16.40% is 102.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for 908 Devices and its competitors. For the Medical Devices & Instruments industry, the median 3-Year EBITDA Growth Rate is 8.10 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. 908 Devices's current 3-Year EBITDA Growth Rate is 16.40%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is 908 Devices stock overvalued right now?
Based on GuruFocus' analysis, 908 Devices (MASS) is currently considered Modestly Overvalued. The stock's GF Value™ is $7.06, compared to a current price of $8.01 — trading 13.5% above its estimated fair value. The current 3-Year EBITDA Growth Rate is 16.40% and 102.5% above the Medical Devices & Instruments industry median of 8.10. 908 Devices' overall GF Score™ is 71/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For 908 Devices (MASS), the current 3-Year EBITDA Growth Rate is 16.40% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is 908 Devices (MASS) Overvalued in 2026?
Based on GuruFocus' analysis, 908 Devices stock appears to be overvalued.
The current stock price of $8.01 is trading 13.5% above its estimated GF Value™ of $7.06.
GuruFocus considers 908 Devices to be Modestly Overvalued.
Key valuation signals for MASS:
3-Year EBITDA Growth Rate: 16.40%
GF Value™: $7.06 vs. price of $8.01 (13.5% above fair value)
Industry Position: 102.5% above the Medical Devices & Instruments median (#269 of 693)
No single metric tells the full story. See the MASS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
908 Devices Inc develops a suite of purpose-built handheld devices for point-of-need chemical analysis. Leveraging mass spectrometry, optical spectroscopy, analytics and machine learning technologies, the company makes devices that are smaller and more accessible than conventional laboratory instruments. Its devices, including MX908, ThreatID, XplorIR and VipIR, are used to analyze unknown materials and provide actionable answers in health, safety and defense technology applications, addressing the fentanyl and illicit drug crisis, toxic carcinogen exposure and security threats. The company reimagines mass spectrometry technology by developing smaller, lower-cost and simpler-to-operate devices compared to conventional instruments, and generates maximum revenue from the United States.
71GF Score
Get the complete analysis for MASS
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MASS has been successfully added to your 
